國家衛生研究院 NHRI:Item 3990099045/14505
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 909923      線上人數 : 804
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/14505


    題名: Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience
    作者: Ting, YL;Su, YY;Chiang, NJ;Chao, YJ;Li, YJ;Huang, CJ;Liao, TK;Su, PJ;Liu, IT;Tsai, HJ;Yen, CJ;Shan, YS;Chen, LT
    貢獻者: National Institute of Cancer Research
    摘要: Background: There is increasing evidence that neoadjuvant chemotherapy in stage III pancreatic cancer resulted in higher rate of conversion surgery and improved survival. This study aims to investigate the practice pattern and how initial treatment strategy impact the outcome of stage III pancreatic ductal adenocarcinoma (PDAC). Methods:During February 2013 to July 2020, 164 stage III PDAC patients treating at National Cheng Kung University Hospital were manually reviewed. This study is approved by the Institutional Review Board (A-ER-108-113) and followed the Declaration of Helsinki. Results:The 164 patients had a median age of 66 (range 27-84), a median albumin of 4.0 g/dl (range 2.5-5.0) and a median CA 199 of 356 U/ml (range 1.5-12000). We observed a paradigm shift with neoadjuvant chemotherapy being the major approach since 2016. The initial treatment strategy was neoadjuvant chemotherapy (NAC) in 127 patients (77.4%), upfront operation (OP) in 19 patients (11.6%) and concurrent chemotherapy (CCRT) in 18 patients (11.0%). The success rate of surgery was significantly higher in NAC group than OP and CCRT group (39% vs. 26% vs 22%). The prognosis was also significantly better in NAC group than OP and CCRT group with corresponding median overall survival (mOS) of 18.6, 9.7 and 9.0 months. For NAC group, the mOS of those with or without conversion surgery was 29.4 months and 14.5 months, respectively. The combination of S-1/leucovorin, oxaliplatin and gemcitabine (SLOG) was the most common used regimen (n=52) followed by modified FOLFIRINOX (n=22). Conclusions: Neoadjuvant chemotherapy was adapted as standard of care in our institute since 2016 and achieved a significantly higher success rate of conversion surgery and improved mOS in patients with stage III PDAC.
    日期: 2022-07
    關聯: Annals of Oncology. 2022 Jul;33(Suppl. 6):S535.
    Link to: http://dx.doi.org/10.1016/j.annonc.2022.05.319
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000834940400408
    顯示於類別:[陳立宗] 會議論文/會議摘要
    [蔡慧珍] 會議論文/會議摘要
    [姜乃榕] 會議論文/會議摘要
    [蘇勇曄] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000834940400408.pdf105KbAdobe PDF133檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋